P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION

• Thomas Kipps,
• Carolyn Owen,
• Ian W. Flinn,
• Paul M. Barr,
• Alessandra Tedeschi,
• Richard Greil,
• Edith Szafer-Glusman,
• Hsin-Hui Huang,
• Lynne Neumayr,
• Chris Abbazio,
• Tait Shanafelt

Affiliations

Thomas Kipps

1 University of California San Diego Moores Cancer Center, San Diego, CA, United States

Carolyn Owen

2 Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada

Ian W. Flinn

3 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States

Paul M. Barr

4 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States

Alessandra Tedeschi

5 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Richard Greil

6 IIIrd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster, Salzburg, Austria

Edith Szafer-Glusman

7 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States

Hsin-Hui Huang

8 AbbVie Company, San Francisco, CA, United States

Lynne Neumayr

7 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, United States

Chris Abbazio

8 AbbVie Company, San Francisco, CA, United States

Tait Shanafelt

9 Stanford University Medical Center, Stanford, CA, United States